March 18, 2022
1 min watch
Save
VIDEO: Sacituzumab and other antibody-drug conjugates for triple-negative breast cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.
Kalinsky, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, said sacituzumab govitecan (Trodelvy, Gilead) is currently the only approved antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer.
"Right now, this is not a frontline agent, but this drug is being evaluated earlier and earlier, including in the operable setting," Kalinsky said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Kalinsky reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.